US Representative

Mike Flood 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 6)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB41

Introduced
1/9/23  
Refer
1/9/23  
VA Same-Day Scheduling Act of 2023 This bill requires the Department of Veterans Affairs (VA) to ensure that when a veteran enrolled in the VA health care system contacts the VA by telephone to schedule an appointment for care or services at a VA facility, the scheduling for the appointment occurs during that telephone call.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4157

Introduced
6/15/23  
Refer
6/15/23  
Not Just a Number Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4263

Introduced
6/21/23  
Refer
6/21/23  
ADINA Act Allergen Disclosure In Non-food Articles Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB427

Introduced
1/20/23  
Refer
1/20/23  
Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4274

Introduced
6/22/23  
Refer
6/22/23  
HERO Act Helping Emergency Responders Overcome Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB431

Introduced
1/20/23  
Life at Conception Act This bill declares that the right to life guaranteed by the Constitution is vested in each human being at all stages of life, including the moment of fertilization, cloning, or other moment at which an individual comes into being. Nothing in this bill shall be construed to authorize the prosecution of any woman for the death of her unborn child.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4313

Introduced
6/22/23  
Refer
6/22/23  
Virginia Graeme Baker Pool and Spa Safety Reauthorization Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4335

Introduced
6/23/23  
VA Loan Informed Disclosure Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4417

Introduced
6/30/23  
Ending Agricultural Trade Suppression Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB448

Introduced
1/24/23  
Putting Investors First Act of 2023 This bill requires a proxy advisory firm to register with the Securities and Exchange Commission and prohibits an unregistered proxy advisory firm from using interstate commerce to provide proxy-voting advice, research, analysis, or recommendations to any client. With respect to these firms, the bill (1) establishes procedures for both registration and termination of registration; (2) requires each firm to employ an ombudsman, designate a compliance officer, and publicly disclose conflicts of interest; (3) allows issuers to assess and comment on proxy voting recommendations; and (4) prohibits unfair, coercive, or abusive practices. The bill establishes a private right of action against a proxy advisory firm that endorses an approved proposal that is not supported by the issuer and is found to be illegal.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4518

Introduced
7/10/23  
Refer
7/10/23  
CARE Act of 2023 Veteran Caregiver Application and Appeals Reform Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4551

Introduced
7/11/23  
Refer
7/11/23  
Protecting Investors’ Personally Identifiable Information Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4563

Introduced
7/11/23  
Refer
7/11/23  
Refer
7/11/23  
ACE Act End Zuckerbucks Act of 2023 Solving an Overlooked Loophole in Votes for Executives (SOLVE) Act Promoting Free and Fair Elections Act Don't Weaponize the IRS Act American Confidence in Elections Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4721

Introduced
7/18/23  
Main Street Tax Certainty Act

Primary Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4642

Introduced
7/14/23  
International Regulatory Transparency and Accountability Act